ResMed news

Mixed outlook with positive portfolio optimization and strong mask segment growth (13% YoY), but offset by Zacks Rank #3 (Hold) rating, 17.7% stock decline over the past year, and headwinds from macroeconomic sensitivity and intense competition. The divestiture is strategic but represents a portfolio reduction.

ResMed is acquiring an innovative FDA-approved medical technology company that addresses unmet medical needs in sleep health. The acquisition strengthens ResMed's position in the sleep health market and expands its connected health ecosystem with a differentiated first-in-class therapy.

ResMed is identified as a key player in the expanding sleep apnea devices market, which is projected to grow at 7.05% CAGR through 2034. The company benefits from increasing prevalence of sleep apnea, technological advancements, and growing homecare adoption trends.

ResMed demonstrates solid fundamentals with 11% YoY revenue growth, rising gross profit margins, 18% operational income growth, and attractive valuation metrics (P/E of 22 vs. 5-year average of 29). Strong digital health ecosystem expansion and R&D investments support future growth, though the article acknowledges some risks like Medicare reimbursement uncertainty and competitive threats.

Q3 fiscal 2026 results exceeded expectations with EPS of $2.86 vs $2.79 estimate, 10.8% YoY revenue growth, expanded gross margins to 62.2%, and Royal Bank of Canada raised price target to $321 with outperform rating

Major player in respiratory care devices market with strong positioning in PAP devices and home healthcare solutions, benefiting from market expansion and aging population trends.